Completed PHASE2 NCT00948142

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections

Sponsor: Arrevus Inc.

Conditions Skin Diseases, Bacterial

Interventions CEM-102 Linezolid

Updated 8 times since 2017 Last updated: Apr 15, 2019 Started: Aug 31, 2009 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

A PHASE2 clinical study on Skin Diseases, Bacterial, this trial is completed. The trial is conducted by Arrevus Inc. and has accumulated 8 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
May 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — May 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arrevus Inc.

Data source: Arrevus Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Butte, United States , Chula Vista, United States , Columbus, United States , Detroit, United States , La Mesa, United States , Los Angeles, United States , Oceanside, United States , Oxnard, United States , Pasadena, United States and 5 more locations